Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deutivacaftor - Vertex Pharmaceuticals

Next Previous
X
Search
Drug Profile

Deutivacaftor - Vertex Pharmaceuticals

Alternative Names: C-10355; C-10358; CTP-656; D-ivacaftor; Deuterated ivacaftor; ivacaftor deuterated; VX 561

Latest Information Update: 10 Mar 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Concert Pharmaceuticals
  • Class Amides; Aminophenols; Antifibrotics; Organic deuterium compounds; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 06 Mar 2023 Concert Pharmaceuticals has been acquired by Sun Pharmaceutical Industries
  • 08 Dec 2022 No development reported - Phase-II for Cystic fibrosis in Australia (PO) (NCT03911713)
  • 08 Dec 2022 No development reported - Phase-II for Cystic fibrosis in Belgium (PO) (NCT03911713)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top